Canaccord Genuity Reiterates a' Buy' on Edwards Lifesciences (EW); SOURCE XT Bodes Well for PARTNER II
Tweet
Share
E-mailGet Alerts EW Hot Sheet
Price: $89.79 -0.04%
Rating Summary:
31 Buy, 14 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Rating Summary:
31 Buy, 14 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a' Buy' on Edwards Lifesciences (NYSE: EW) price target of $93.00.
Analyst, Jason R. Mills, said, "SOURCE XT showed a 30-day mortality rate of 6.3% vs. 8.8% in the original SOURCE registry. We believe the mix of T-F/TA patients, as well as baseline characteristics, affected outcomes. Specifically, renal dysfunction was associated with higher mortality rates in SOURCE, yet 28% of SOURCE XT patients had renal insufficiency, suggesting that some European physicians may not be applying previous learnings to patient selection. We don’t think that’s the case in the US. This, combined with improved outcomes in SOURCE XT, makes us optimistic on PARTNER II results."
For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.
Shares of Edwards Lifesciences closed at $82.60 yesterday.
Analyst, Jason R. Mills, said, "SOURCE XT showed a 30-day mortality rate of 6.3% vs. 8.8% in the original SOURCE registry. We believe the mix of T-F/TA patients, as well as baseline characteristics, affected outcomes. Specifically, renal dysfunction was associated with higher mortality rates in SOURCE, yet 28% of SOURCE XT patients had renal insufficiency, suggesting that some European physicians may not be applying previous learnings to patient selection. We don’t think that’s the case in the US. This, combined with improved outcomes in SOURCE XT, makes us optimistic on PARTNER II results."
For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.
Shares of Edwards Lifesciences closed at $82.60 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Emkay Global Starts Urban Company (URBANCO:IN) at Buy (1)
- Deere (DE) PT Raised to $585 at JPMorgan
- ICICI Securities Resumes Dalmia Bharat Ltd (DALBHARA:IN) at Add (2)
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
